Sage Therapeutics (NASDAQ:SAGE) Price Target Lowered to $18.00 at Mizuho

Sage Therapeutics (NASDAQ:SAGE) had its target price lowered by Mizuho from $20.00 to $18.00 in a report issued on Friday morning, Benzinga reports. Mizuho currently has a neutral rating on the biopharmaceutical company’s stock.

Several other research firms have also recently weighed in on SAGE. Oppenheimer cut their price objective on shares of Sage Therapeutics from $25.00 to $17.00 and set a market perform rating for the company in a research report on Thursday, April 18th. Needham & Company LLC reaffirmed a hold rating on shares of Sage Therapeutics in a research report on Thursday. TD Cowen cut their price target on Sage Therapeutics from $30.00 to $16.00 and set a buy rating on the stock in a report on Thursday, April 18th. Wedbush restated a neutral rating and set a $24.00 price objective on shares of Sage Therapeutics in a report on Wednesday, April 17th. Finally, Scotiabank cut their target price on Sage Therapeutics from $34.00 to $19.00 and set a sector outperform rating on the stock in a report on Thursday, April 18th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of Hold and a consensus price target of $37.72.

Sage Therapeutics Trading Up 0.8 %

Shares of NASDAQ:SAGE opened at $13.69 on Friday. Sage Therapeutics has a 52-week low of $10.92 and a 52-week high of $59.99. The company has a 50-day simple moving average of $18.56 and a 200 day simple moving average of $20.64.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). The business had revenue of $7.90 million during the quarter, compared to analyst estimates of $5.26 million. Sage Therapeutics had a negative net margin of 552.52% and a negative return on equity of 54.17%. The business’s quarterly revenue was up 139.4% on a year-over-year basis. During the same period in the previous year, the business earned ($2.46) earnings per share. On average, equities research analysts anticipate that Sage Therapeutics will post -6.3 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. CWM LLC raised its stake in shares of Sage Therapeutics by 274.2% during the 3rd quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 883 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Sage Therapeutics by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 748 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Sage Therapeutics by 17.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,289 shares of the biopharmaceutical company’s stock valued at $191,000 after acquiring an additional 1,375 shares during the last quarter. Values First Advisors Inc. bought a new position in shares of Sage Therapeutics during the 3rd quarter valued at approximately $219,000. Finally, Quest Partners LLC bought a new position in shares of Sage Therapeutics during the 4th quarter valued at approximately $261,000. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.